Press releases
June 2009
Genewave has been awarded a grant: the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections.
Genewave S.A.S. has been awarded a grant by the French funding agency for innovating small businesses: the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections receives a total of 9 million euros from OSEO-ISI.
The aim of the project is to develop a therapeutic adjuvant against the spread of antibiotic resistance of bacteria, a diagnostics test for patients infected by multi-drug-resistant bacteria and novel antibiotics.
The NOSOBIO consortium comprises 6 partners: 4 biotech SMEs (including 2 companies incorporated at Genopole: Serial Genetics and Genewave, as well as Palumed and Da Volterra), and 2 academic institutions, Institut Pasteur and Assistance Publique-Hôpitaux de Paris.
For additional information, download the complete Press Release (in French).
May 2009
Product Demonstration in AMT-LOC-MDE 2009 Conference, Stockholm
20 May 2009 at 10:30, Coffee Break, Booth #34
HybLive is a fully automated microarray system that combines hybridization, washing, melting and real-time fluorescence imaging in a compact benchtop package.
HybLive is the first open microarray platform allowing real-time measurement of the on-slide hybridization and melting of target molecules to thousands of probes simultaneously. It enables a variety of experiments unachievable with conventional microarray tools, encompassing quick determination of optimal hybridization conditions, rapid verification and validation of probe design, environmental sample monitoring, multiplex on‐chip melting curves determination, on‐chip molecule interaction studies... With its excellent sensitivity and discriminative power, HybLive also enables reliable genotyping studies and even SNP discrimination using genomic DNA.
For additonal information, visit the HybLive webpage
April 2009
PORTFASTFLU : Development of a diagnostic system for INFLUENZA
28th april 2009
Genewave, Coordinator of PORTFASTFLU - European project to develop rapid screening system that will revolutionise control of INFLUENZA epidemics.
PORTFASTFLU is a €3.8 million, European Union FP7 funded project (www.portfastflu.com) which aims to develop and validate a rapid diagnostic system for influenza that will be used for surveillance and early detection of influenza, and as a point-of-care tool in developed and developing countries.
The system will be fully automated, and will combine microfluidic based RNA extraction and RT-PCR with real-time microarray in one small footprint machine. The device will allow on site detection of influenza virus in clinical or veterinary samples, including avian and current porcine flu, as well as H and N subtyping of the other various influenza known viruses.
Partners in the Portfastflu research project are Coordinator Genewave (Ecole Polytechnique of Palaiseau, Genopole Evry, France), Nottingham Trent University (Nottingham, UK), Biosensia (Dublin, Ireland), CIRAD (Montpellier, France), VIB University of Ghent (Ghent, Belgium), Ikerlan (Mondragon, Spain), Gaiker (Zamudio, Spain), Basque Foundation for Health Innovation and Research (San Sebastian, Spain), and Whatman (Maidstone, UK).
The technology would improve the diagnosis time for all forms of influenza, including H5N1 avian influenza and H1N1 porcine flu. In the event of an emerging pandemic Influenza, the ability to rapidly diagnose and type influenza virus in the field would have enormous impact on the spread of the outbreak, reducing human cases and mortality rates.
The technology could also prove to be a vital tool in the fight against high and low pathogenic avian influenza, making it possible to set up exclusion zones and cull infected birds much faster, before infection spreads. This preventative measure is seen by many countries as highly beneficial to the controversial use of avian influenza vaccines.
Halfway through the project (April 2009), capacity to identify the various strains (type A, H1N1, H2N3, H3N2, H5N1, H5N2, H7N1, H7N7, H9N2, H9N9 et type B) has been demonstrated. Clinical tests in hospitals and in the field will start in December 2009.
Matrix of detected influenza strains
Dr. Alan McNally, Senior Lecturer at Nottingham Trent University, partner in PORTFASTFLU consortium, mentionned the project in a BBC radio interview.
Download the complete Press Release.
June 2008
SNP Detection with HybLive™ Real-Time Microarray Platform
HybLive™ is an innovative real-time microarray instrument that integrates hybridization, active mixing, temperature control and a live fluorescence microarray imaging into a compact benchtop package. HybLive™ allows to perform a variety of experiments unachievable with conventional biochip tools, such as quick multiplex on-chip melting curve determination, reliable genotyping, on-chip protein interaction studies, optimization of hybridization conditions, etc.
The performances of HybLive™ are here highlighted focusing on Single Nucleotide Polymorphism (SNP) detection using an envirnomental model: the bacteria Sinorhizorbium meliloti.
This application takes advantage of excellent benefits of this new biochip tool for:
- The optimization of hybridization parameters; Real-Time monitoring of the whole process;
- The enhanced specificity in sequence discrimination; Efficient stirring and adjustable temperature.
Summary
HybLive™ allows a fast and easy way to optimize multiple parameters for SNP detection experiments: optimal temperature for best mismatch discrimination, minimal duration required for hybridization, optimal stringency.
HybLive™ provides high sensitivity and specificity critical for SNP detection characterization (excellent mismatch discrimination).
HybLive™ promises to be a diagnostic tool for fast and high throughput multiplex SNP discrimination
May 2008
Launch of the First Real-Time Microarray Platform: HybLive™
Genewave to Launch HybLive™, a Fully Automated Real-time Microarray Platform, at AMT Conference in Barcelona.
PALAISEAU, France, May 5, 2008 -- Genewave S.A.S. today announced that it will introduce HybLive™, its fully automated microarray platform, at AMT Conference in Barcelona on May the 7th and 8th. HybLive™ combines hybridization, washing, melting and real-time fluorescence imaging in a compact benchtop package.
HybLive™ is the first open microarray platform allowing real-time measurement of the on-slide hybridization and melting of target molecules to thousands of probes simultaneously. It enables a variety of applications such as rapid verification and validation of probe design, environmental sample monitoring, multiplex on-chip melting curves determination, on-chip DNA and protein interaction studies... With its high sensitivity and excellent discriminative power, HybLive™ also enables reliable genotyping studies and even SNP discrimination using unamplified genomic DNA.
"We are proud to launch a new cutting-edge real-time microarray technology, the result of several years of research and development by Genewave’s dedicated team of physicists, engineers and molecular biologists", said Claude Weisbuch, PhD, co-founder of Genewave and Chief Scientist. “HybLive is an extremely versatile automated instrument allowing a range of microarray experiments unachievable with conventional end-point measurement tools. HybLive’s fully programmable process control combined to its real time monitoring of fluorescence signal enables easy and fast optimization of hybridization conditions or in silico probe design. Moreover the proprietary active mixing technology implemented in HybLive allows a significant reduction of hybridization time. This feature combined with the walk-away operation set-up results in important time and cost savings”, Weisbuch continued.
“A pre-launch presentation of HybLive real-time system at the Analytica Trade Fair last April in Munich attracted a lot of interest from visitors”, said Constantin Nelep, PhD, Business Development Manager of Genewave. “HybLive technology has been designed as a true open platform fully compatible with standard format microarray slides. Thus HybLive can be easily integrated into any microarray lab workflow used to handle their custom-printed arrays. Moreover HybLive with its automation, user-friendly interface and analysis software is an all-in-one solution for researchers looking for an easy access to microarray technology as custom or commercial arrays can be purchased from Genewave or other suppliers,” Nelep further explained.
The integration of the whole biochip workflow into one compact system goes towards the development of “one-touch” instruments for multiplexed diagnostics applications and routine analysis. “Right now HybLive technology allows Genewave to further develop its OEM offer for industrial customers, which was successfully started last year with the release of DiagArray OEM microarray readers”, Nelep said.